Cargando…

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

INTRODUCTION: Since treatment modalities for metastatic recurrent triple-negative breast cancer (mrTNBC) are limited, a novel treatment approach including immunotherapy is required. We have developed a novel regimen of personalized peptide vaccination (PPV), in which vaccine antigens are individuall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Ryuji, Toh, Uhi, Iwakuma, Nobutaka, Takenaka, Miki, Otsuka, Hiroko, Furukawa, Mina, Fujii, Teruhiko, Seki, Naoko, Kawahara, Akihiko, Kage, Masayoshi, Matsueda, Satoko, Akagi, Yoshito, Yamada, Akira, Itoh, Kyogo, Sasada, Tetsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227005/ https://www.ncbi.nlm.nih.gov/pubmed/24992895 http://dx.doi.org/10.1186/bcr3685

Ejemplares similares

FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis
por: TAKENAKA, MIKI, et al.
Publicado: (2013)

Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy
por: TAKAHASHI, RYUJI, et al.
Publicado: (2013)

Clinical outcomes of patients after nipple-sparing mastectomy and reconstruction based on the expander/implant technique
por: Toh, Uhi, et al.
Publicado: (2020)

Evaluation of contrast Sonazoid-enhanced ultrasonography for the detection of hepatic metastases in breast cancer
por: Mishima, Mai, et al.
Publicado: (2014)

Predictive factors of the tumor immunological microenvironment for long‐term follow‐up in early stage breast cancer
por: Okabe, Mina, et al.
Publicado: (2017)

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
por: Takahashi, Ryuji, et al.
Publicado: (2013)

Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer
por: Toh, Uhi, et al.
Publicado: (2020)

Primary breast peripheral T-cell lymphoma not otherwise specified: report of a case
por: Muroya, Daisuke, et al.
Publicado: (2014)

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
por: Azuma, Koichi, et al.
Publicado: (2014)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
por: Iwasa, Satoru, et al.
Publicado: (2016)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022)

Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
por: Fukui, Akimasa, et al.
Publicado: (2012)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
por: Yutani, Shigeru, et al.
Publicado: (2015)

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Expression of MAGE‐1 Gene by Esophageal Carcinomas
por: Toh, Yuji, et al.
Publicado: (1995)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
por: Komatsu, Nobukazu, et al.
Publicado: (2013)

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
por: Waki, Kayoko, et al.
Publicado: (2014)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Maximum Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography and Glucose Transporter-1 Expression Correlates With Survival in Invasive Ductal Carcinoma of the Pancreas
por: Kitasato, Yuhei, et al.
Publicado: (2014)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2016)

Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer
por: Kawahara, A, et al.
Publicado: (2009)

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

Evaluation of the expression of bone marrow‐derived mesenchymal stem cells and cancer‐associated fibroblasts in the stroma of gastric cancer tissue
por: Minami, Taizan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_24fablqkkahnkl66vepdcks3mj